Product sales from Olverembatinib in the first half of 2025 increased 93%year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced ...

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient recruitment to trial design and long-term strategy.

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Over 50 Patients Enrolled Thus Far in Phase 2b Trial of Halneuron® in ...

The trial aims to assess the regimen over a 90-day period for those with a presumptive diagnosis of the condition.

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global ...

Historically, more than half of patients with GM2 gangliosidosis need to be fed via IV between 13 and 18 months of age. In ...